{
    "organizations": [],
    "uuid": "163ec440b7e85586ec705aa1a841418e66311c22",
    "author": "",
    "url": "https://www.reuters.com/article/brief-oramed-initiates-its-90-day-pivota/brief-oramed-initiates-its-90-day-pivotal-dose-ranging-clinical-study-for-oral-insulin-idUSFWN1S00OO",
    "ord_in_thread": 0,
    "title": "BRIEF-Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study For Oral Insulin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 23, 2018 / 12:25 PM / Updated 12 minutes ago BRIEF-Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study For Oral Insulin Reuters Staff 1 Min Read \nApril 23 (Reuters) - Oramed Pharmaceuticals Inc: \n* ORAMED INITIATES ITS 90-DAY PIVOTAL DOSE-RANGING CLINICAL STUDY FOR ORAL INSULIN Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-04-23T15:25:00.000+03:00",
    "crawled": "2018-04-23T15:41:03.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "initiate",
        "pivotal",
        "clinical",
        "study",
        "oral",
        "insulin",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "oramed",
        "pharmaceutical",
        "inc",
        "oramed",
        "initiate",
        "pivotal",
        "clinical",
        "study",
        "oral",
        "insulin",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}